VistaGen Therapeutics (VTGN) reported Q2 revenue

VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.54). Revenue for the quarter came in at $258 million.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• One investor reportedly took a third of Viking’s share sale
• Microsoft's CEO is putting Brad Smith in charge of communications - Business Insider